SEARCH

SEARCH BY CITATION

Keywords:

  • chondroitin sulfate;
  • extracellular matrix;
  • glycosaminoglycan;
  • growth factor;
  • heparan sulfate;
  • intracellular;
  • mammalian cell;
  • proteoglycan;
  • recombinant;
  • structure

Abstract

  1. Top of page
  2. Abstract
  3. Introduction
  4. Extracellular matrix proteoglycans
  5. Cell-surface proteoglycans
  6. Intracellular proteoglycans
  7. Conclusions
  8. References

Proteoglycans are ubiquitous dynamic molecules that are made up of a protein core to which specific linear glycosylation structures, known as glycosaminoglycans, have been covalently coupled. They have roles in many biological and pathological processes, which have been shown to be dependent on events involving the protein component and/or the glycosaminoglycan chains. This review focuses on the literature describing the recombinant expression and production of proteoglycans known to be present in the extracellular, cell surface and intracellular environments with an emphasis on how the structure of the molecule relates to its biological function and how this relationship has been explored using recombinant DNA technology for clinical applications.


Abbreviations
CHO

Chinese hamster ovary

COS

African monkey kidney

CS

chondroitin sulfate

CSPG4

chondroitin sulfate proteoglycan 4

DS

dermatan sulfate

ECM

extracellular matrix

FGF

fibroblast growth factor

G1/2/3

globular 1/2/3

GAG

glycosaminoglycan

GalNAc

2-(acetylamino)-2-deoxy-d-galactose

HA

hyaluronan

HC

heavy chain

HEK-293

human embryonic kidney cell line

HeLa

human cervical cancer

HS

heparan sulfate

HT-1080

human fibrosarcoma

IG

interglobular

KS

keratan sulfate

NG2

nerve/glial antigen 2

PG

proteoglycan

Sf

Spodoptera frugiperda

TGF

transforming growth factor

Introduction

  1. Top of page
  2. Abstract
  3. Introduction
  4. Extracellular matrix proteoglycans
  5. Cell-surface proteoglycans
  6. Intracellular proteoglycans
  7. Conclusions
  8. References

This review discusses the expression and characterization of recombinant proteoglycans (PGs), how they have been used to advance our understanding of the relationship between PG structure and function, and how they might be useful in clinical applications in future.

PGs are multifunctional macromolecules that occur intracellularly, at the cell surface or in the extracellular matrix (ECM), and are involved in biological and pathological processes. Glycosaminoglycan (GAG) side chains dominate the functions of many PGs, whereas other PGs are known to occur in both glycosylated and unglycosylated forms, suggesting that the protein core is also important for many biological functions. The roles of PGs in biology and pathology are diverse and complex, and cover such areas as: the physical effects imparted on cartilage tissue via the binding of water molecules to the GAG chains decorating aggrecan; the finely orchestrated and dynamic events seen in embryonic development and organogenesis, where mitogen/morphogen gradients are established and continually modified via an equilibrium between cell-surface syndecans and glypicans; and extracellular heparan sulfate (HS) PGs like perlecan, agrin and type XVIII collagen.

PGs are composed of protein cores that are modified in a post-translational fashion with one or more GAG chains, which are long linear carbohydrate chains that are made up of repeating disaccharide units consisting of an N-acetylated hexose sugar linked to a hexuronic acid that has been named on the basis of the tissue from which it were first isolated. For example, chondroitin sulfate (CS) from cartilage, dermatan sulfate (DS) and keratan sulfate (KS) from skin, and HS and heparin from liver. Expression of the protein core is driven by a well-understood process which, because of the advent of DNA recombinant technology in the late 1980s and 1990s, meant that large quantities of known protein could be produced for use in laboratories or eventually the clinic. This started with the use of Escherichia coli-based expression systems, which had limited success in the production of large molecular mass proteins, proteins that had extensive folding and tertiary structure due to disulfide bridge formation and proteins with extensive glycosylation. Most of these factors apply to the PG family of molecules, particularly the large protein cores seen in the extracellular group of PGs. The challenge of obtaining glycosylation using E. coli systems is focused on using glyco-engineering approaches that utilize hybrid cell systems and have resulted in the fusion of bacterial strains that possess some of the intracellular machinery to achieve N-linked glycosylation with E. coli [1, 2]. These hybrid E. coli strains are still unable to O-glycosylate proteins, meaning that they are not suitable for the expression of PGs. Yeast expression systems using Saccharomyces cerevisiae or Pichia pastoris [3] and viral expressions systems using Spodoptera frugiperda (Sf9) insect cells [4] as hosts have been used with some success for the expression and glycosylation of PGs; the infection of mammalian cells has also provided some success for the production of biglycan and decorin [5]. Most of the focus in this area has been on the use of mammalian expression systems that utilize the Chinese hamster ovary (CHO) cell line [6] or the human embryonic kidney cell lines, HEK-293/293T. HEK-293 expression systems have the advantage of decorating the protein core in a similar GAG structure to the native molecules. For example, recombinant endocan was shown to be similar with respect to disaccharide composition to that produced by human umbilical venous endothelial cells under native conditions, however, the size and therefore the length of the recombinant GAG chains was significantly greater [7]. A significant challenge that remains for the production of recombinant PGs and their domains by these mammalian expression systems is the production of GAG chains that have similar lengths and sulfation patterns to that produced by the cell of interest. The HS attached to recombinant domain I of perlecan expressed in HEK-293 cells was approximately half the length of that attached to endothelial-cell-derived full-length perlecan and was produced as part of a heterogenous group of molecules decorated with HS, CS and KS. This is in contrast to the endothelial cell form which was decorated with HS only [8]. Interestingly, the full-length perlecan produced by the HEK-293 cells was also decorated with HS, CS and KS [9], indicating that each cell type may have a different set of post-translational modification enzymes that produce GAG chains specific for each cell type.

The synthesis of GAG chains takes place in the Golgi and is initiated by xylosylation of certain serine residues on the protein core that are present in consensus sequences. The linkage region is then built sequentially, residue by residue, resulting in a linkage tetrasaccharide with the sequence GlcAβ1–3Galβ1–3Galβ1–4Xyl-ol that is identical for all CS/DS- and HS/heparin-containing GAGs. The decision to generate either CS/DS or HS/heparin is defined by the addition of the next residue to this structure with the addition of GlcNAc dictating the generation of HS/heparin structures, whereas the addition of 2-(acetylamino)-2-deoxy-d-galactose (GalNAc) will generate CS/DS structures. Although the ribosomal-localized mechanisms involved in synthesis of the protein core are relatively well understood, many of the aspects of the Golgi-based glycosylation processes remain elusive, including what controls the addition of the first xylose of the linkage tetrasaccharide to what serine residue so that it can become decorated with GAGs and what dictates whether a HS/heparin chain or a CS/DS chain is produced. It has been suggested that the default pathway for GAG addition may be the addition of CS, but it has recently been suggested that the GAG decoration type was due to residence time in the Golgi where the various chain-modification enzymes are embedded and localized in the Golgi membranes [10]. The other factor involved in the generation of GAG chains is the vast complexity that is provided via the addition of sulfate residues at various points along the polymerized chain. HS/heparin chains are more highly sulfated than CS/DS chains and contain more complexity, with heparin containing relatively more sulfate than HS and relatively more DS than CS. HS/heparin chains are also modified via deacetylation prior to sulfation on some GlcNAc residues and epimerization of some glucuronic acid residues into iduronic acid (IdoA). DS shares some of these modifications with HS in that it may also contain iduronic acid as well as 2-sulfated iduronic acid. There are five different enzymes in humans, many of which have up to six or seven isoforms that have been shown to be expressed at different levels in different tissues to produce a modified HS/heparin chain in a precisely controlled and well-orchestrated fashion. The initial steps of the sulfation process occur by the removal of an acetyl group from a GlcNAc and the addition of sulfate at various points along the chain, which undergo further sulfation around that initial GlcNAc, resulting in the generation of sulfate or S-domains. The S-domains are interspersed by relatively longer regions of unsulfated acetylated saccharides that usually account for 70% of the residues in an HS chain and significantly less in a heparin chain, which tend to be completely sulfated [11].

When genes for PGs are transfected into mammalian cells, the amounts of transcript and protein core increase and, following Michaelis–Menton kinetics, the amount of PG would increase until the rate-limiting enzyme reached its maximum velocity. This results in an increase in the amount of protein core that is undecorated as well as an increase in PGs with GAG chains that might be shorter or lacking certain modifications. This leads to an increase in the heterogeneous nature of the recombinant forms of PGs produced and the potential requirement of transfecting the cells with the genes for the enzymes [12]. When chondroitin sulfate proteoglycan 4 (CSPG4) was transfected into HEK-293 cells, two PG populations were isolated with one being substantially present as a protein core [13]. Given that HS/heparin chains contain the greatest degree of complexity, it will be interesting to investigate how cells that are transfected with the serglycin gene produce PGs decorated with GAG chains that are similar in structure and function to those present in the granules of neutrophils, platelets and mast cells. Recently, there has been some success in bioengineering heparin in the laboratory using microfluidic-based bioreactors [14]. In future, it will be challenging but exciting to see the development of laboratory bioreactors designed to take the enzyme kinetics into account so that a synthetic PG can be manufactured.

Extracellular matrix proteoglycans

  1. Top of page
  2. Abstract
  3. Introduction
  4. Extracellular matrix proteoglycans
  5. Cell-surface proteoglycans
  6. Intracellular proteoglycans
  7. Conclusions
  8. References

Recombinant DNA technology has enabled the expression and biochemical characterization of several ECM PGs, including the small leucine-rich PGs, decorin and biglycan, and other CS PGs including aggrecan, versican and bikunin. In addition, the HS PGs including perlecan, endocan, types XVIII and XV collagen are described below.

Decorin

Decorin and biglycan are members of the small leucine-rich PG family and are structurally similar with leucine-rich repeats that are flanked by cysteine-rich domains [15]. Small leucine-rich PGs are usually decorated with CS, DS or KS with decorin displaying tissue-specific GAGs with CS in bone and DS in cartilage and skin [15]. Decorin, also known as DS PG II, has a core protein of 40 kDa which is decorated with one CS or DS chain that ranges in size from ~ 40 to 80 kDa [16, 17]. Decorin is found in the ECM of many tissues including skin, tendon, ligament and articular cartilage and has been shown to bind to a variety of molecules including fibronectin, transforming growth factor (TGF)-β and collagen types I, II [18] and VI [19]; it regulates fibrilogenesis.

Human decorin has been expressed as a CS PG in a variety of cell types including CHO cells [17], human fibrosarcoma (HT-1080) cells [20], HEK-293 cells [18, 21], human gingival fibroblasts [22] and human adenocarcinoma (A549) cells [23]. Human decorin expressed in CHO cells [17] was found to contain different linkage hexasaccharide structures including ΔHexAα1–3GalNAc(4S)β1–4IdoAα1–3Galβ1–3Galβ1–4Xyl-ol indicating that the GAG chain carried some DS disaccharides, ΔHexAα1–3GalNAc(4S)β1–4GlcAα1– 3Galβ1–3Galβ1–4Xyl-ol and ΔHexAα1–3GalNAcβ1–4GlcAα1–3Galβ1–3Galβ1–4Xyl-ol [24]. Decorin from human skin fibroblasts expressed in HT-1080 cells was produced as a mixed population, 25% of which was not decorated with GAGs with the remainder decorated with ~ 20–30 kDa CS [20]. The estimated yield was 30 mg from 109 cells in 24 h. The PG form was found to be two distinct populations, one with the larger CS chain containing predominantly 4-sulfated CS disaccharides and the other containing ~ 55% 4-sulfated CS disaccharides, 15% 6-sulfated CS disaccharides and the remainder unsulfated CS disaccharides [20]. Decorin has been expressed in other cell types including rat glioma cells [25], human cervical cancer (HeLa) cells [26], WiDr colon carcinoma [27] and A431 squamous carcinoma cells [27], CNS-1 glioma cells [28], rat mesangial cells [29] and HEK-293 [30], but has not been characterized with respect to GAG decoration. Mouse decorin has been expressed as a CS PG in HeLa cells [31] and found to contain 4-sulfated CS disaccharides [32]. Bovine decorin has also been expressed in E. coli [33] and human decorin in Spodoptera frugiperda 21 (Sf21) cells [34].

Analysis of recombinantly expressed decorin determined that it must be decorated GAGs and/or N-linked oligosaccharides to be secreted [35]. Recombinantly expressed decorin has also been explored to understand how it interacts with ECM proteins. It has been shown that decorin protects collagen types I and II fibrils against collagenase degradation [36], whereas the interaction between decorin and collagen type I has been shown to involve leucine-rich repeats 5–6, including Arg207 and Asp210 [37]. The N-terminus of decorin has been shown to bind to fibrinogen in the presence of Zn2+ [38]. Decorin expressed in human gingival fibroblasts was found to decrease the protein levels of MMP-1 and -3 suggesting that decorin can modulate tissue remodelling by balancing ECM synthesis and degradation [22]. Decorin also binds the first subcomponent of the C1 complex of the classical pathway of complement activation, C1q, via both the collagen and globular domains and although decorin binds C1, it does not activate complement [39].

Recombinantly expressed decorin has been used to understand how it affects cell behaviour. Full-length decorin decorated with GAGs has been shown to control cell proliferation by reducing the saturation density and changing the morphology of cells [18]. Decorin has been shown to inhibit the proliferation of tumour cells in vitro [27, 40] including human prostate cancer cell lines [30] and breast cancer cells [41]. Decorin has also been shown to reduce primary tumour growth by 50% in mice with orthotopic mammary carcinoma xenografts [41]. The addition of decorin to tumour cells caused suppression of vascular endothelial growth factor mRNA and protein, indicating that decorin might affect tumour growth by suppressing angiogenic stimuli [42]; it can also reduce the motility and invasion of the LM8 murine osteocarcoma cell line [43]. Decorin was also found to suppress epidermal growth factor receptor and androgen receptor expression and phosphorylation which inhibited phosphatidylinositol 3-kinase and Akt phosphorylation and led to apoptosis in LNCaP human prostate cancer cells [30]. This indicates that decorin may be a promising therapy for prostate cancer. Decorin-expressing tumours show more T-cell infiltration, but less activation of microglial cells because decorin suppresses TGF-β synthesis which regulates microglial cell growth and activity [25].

Decorin has been explored for the treatment of glomerulonephritis and in the prevention of glomerulosclerosis [44]. Intravenously injected recombinant decorin was found to be rapidly removed from the circulation and accumulate in the liver before being cleared [45]. Ex vivo decorin gene transfer to rat mesangial cells decreased the levels of TGF-β1 and matrix expansion, which may be useful in the treatment of kidney disease [29].

Decorin has also been explored for repair of the central nervous system and muscle injuries, and as an anti-fibrotic agent. The interaction between decorin and TGF-β has been explored by treating penetrating incisional wounds of rat brains with recombinant human decorin which was found to attenuate all aspects of central nervous system scarring, including matrix deposition and inflammation [46]. Muscle injuries are slow to repair and can result in incomplete functional recovery. Administration of recombinant human decorin has been shown to improve recovery strength, enhance muscle regeneration and inhibit fibrosis in a murine muscle model [47]. Decorin has also been shown to reduce neointimal thickening in balloon-injured rat carotid arteries by increasing the synthesis of collagen type I for enhanced contraction [48]. Gene delivery of decorin in spontaneously hypertensive rats was found to inhibit hypertension-induced cardiac fibrosis, remodelling and hypertrophy [49]. Streptococcus anginosus group pathogens have been shown to bind to decorin via its GAG chain which has implications for dental abscesses [32].

Biglycan

Biglycan consists of a protein core of 42 kDa and contains two CS/DS attachment sites located at the N-terminus, however, it is predominantly only decorated with one GAG chain which is tissue specific [50-52]. Recombinant biglycan has been predominantly expressed in mammalian cell culture systems including HEK-293, CHO and HeLa cells. Recombinant biglycan produced by stably transfected HEK-293 and CHO cells was found to be a mixed population decorated with one or two GAG chains that may be CS or HS [53]. By contrast, biglycan transiently expressed in HT-1080 and rat osteosarcoma (UMR106) cells was found to be a mixed population decorated with one or two CS chains or not decorated with a GAG chain [50], whereas biglycan expressed in Epstein–Barr virus-expressing (293-EBNA) cells was produced in both a PG and protein form, however, the GAGs were not characterized [54]. Recombinant biglycan produced by the HT-1080 cells appeared to be decorated with more than CS because chondroitinase ABC did not completely remove all of its GAG chains [50]. Biglycan expressed in HeLa cells was reported to be decorated with CS [55], whereas mouse biglycan expressed in HeLa cells was decorated with CS types A and C [32].

Mutations in the protein core of biglycan at GAG-attachment sites, serines 42 and 47, have been explored to understand how GAG chain attachment is regulated because PG forms of biglycan exist with either one or two GAG chains [53]. In all the mutations explored, the GAG-attachment site at serine 42 was almost always decorated, irrespective of the presence or absence of the serine 47 site, whereas decoration of serine 47 was dependent on the presence of serine 42 [53]. It was also shown that the C-terminal GAG-attachment site is usually only decorated once the N-terminal site is decorated. The expression and use of recombinant biglycan have led to the discovery of the role of biglycan in organizing collagen type VI into a hexagonal-like network that is dependent on the presence of GAG chains [56]. Recombinant biglycan has also been shown to bind to collagen type I [57], collagen type V, C1q [50] and to mannose-binding lectin, leading to inhibition of the lectin pathway [39].

The use of recombinant biglycan has also elucidated that biglycan is important for the maintenance of muscle cell integrity and plays a direct role in regulating the expression and sarcolemmal localization of the intracellular signalling proteins dystrobrevin-1 and -2, α- and β1-syntrophin and neuronal nitric oxide synthase [54]. In addition, biglycan increases utrophin expression in cultured myotubes and improves muscle function [58]. Biglycan has been shown to bind to Streptococcus anginosus bacteria via its CS chain [32].

Decorin/biglycan chimeras have also been produced to analyse the interactions between decorin and type I collagen [55] which was found to be the result of multiple binding sites acting in concert. In addition, biglycan–decorin chimeras have been shown to bind α- and γ-sarcoglycan [59].

Aggrecan

Aggrecan contains a large protein core of 220 kDa that is decorated with both CS and KS. The protein core of aggrecan is composed of six domains, including: globular 1 (G1), interglobular (IG), globular 2 (G2), KS, CS and globular 3 (G3). Many different recombinant fragments of aggrecan have been produced, although few have been characterized with respect to GAG decoration (Table 1). Full-length bovine aggrecan has been expressed in African monkey kidney (COS-7) cells and was found to be decorated with CS [60]. One study produced 14 different recombinant constructs of aggrecan including each of the six domains individually, and combinations thereof, in COS-7 cells [61]. The recombinant proteins containing the CS, KS or IG domains were found to be decorated with GAGs as deduced from polydisperse relative molecular mass bands in western blots, however, their structure was not determined [61]. When the IG domain was expressed alone it was found to be decorated with GAGs, however, the IG–G2 domain construct had a reduced amount of GAGs. Similarly, the free KS domain was not as extensively GAG decorated as the G1–KS construct [61]. Recombinant human G1–G2 has been expressed in primary bovine keratocytes using a vaccinia virus expression system and found to be decorated with N-linked KS [62]. Link protein has been expressed as a fusion protein with chicken aggrecan CS and G3 domains in COS-7 cells, which was reported to be decorated with CS [63]. A fusion protein containing the CS and G3 domains of rat aggrecan have been expressed in COS-7 cells and found to contain a protein core of 70 kDa decorated with CS [64].

Table 1. Recombinantly expressed forms of aggrecan. nd, not determined; ns, not specified; no GAG, not decorated with GAGThumbnail image of

Other recombinantly expressed fragments of aggrecan reported were either not decorated with GAGs or their GAG decoration was not investigated. The G1 domain of avian aggrecan has been expressed in COS-7 cells, as well as in NIH3T3 and chicken chondrocytes [65], Spodoptera frugiperda, Sf21 insect cell line [66] and High Five insect cells [67]. Transgenic proteins of the G1 domain of aggrecan have also been expressed in CHO cells [68], whereas three subdomains of the G1 domain, A, B and B′, have been expressed in HEK-293 cells individually, and as fusions of two these subdomains with the G2 domain [69]. In addition, a fusion of the G1, IG and G2 domains has been expressed in HEK-293 cells [69]. Fusion proteins containing G1, CS and G3 derived from avian aggrecan have been expressed in CHO cells, but were not characterized with respect to GAG decoration [70]. Human aggrecan IG domain has been expressed in E. coli [71] and COS cells, but it was not decorated with KS [72], which is in contrast to when the IG domain was expressed in COS-7 cells [61]. Recombinant human aggrecan G1–G2 domains have been expressed in Spodoptera frugiperda, Sf21, insect cell line but this construct was not decorated with KS [73]. The G3 domain of human aggrecan has been expressed in E. coli [74, 75]; a fusion protein containing 20% of the CS domain as well as the G3 domain has also been expressed in E. coli [75].

Recombinantly expressed fragments of aggrecan have been used to understand the role of its different domains. Expression of the G1 and G2 domains revealed that these domains are poorly secreted and accumulate in the endoplasmic reticulum [70, 76], whereas the CS and G3 domains are required for efficient secretion of the protein core [77, 78] which is mediated through cysteine-dependent disulfide bonds in the G3 domain [78]. In addition, the G3 domain was found to enhance GAG-attachment [78]. Transgenic G1 domain proteins expressed with two alanines juxtaposed at the C-terminus affected intracellular localization, were not modified in the Golgi and were not efficiently secreted [61, 68], whereas addition of the G3 domain enabled efficient secretion of the protein [68].

Other studies have used recombinantly expressed aggrecan to understand cleavage specificity as well as interactions with the ECM and cells. Studies using incremental deletion and site-directed mutagenesis of the G3 domain expressed in COS-7 cells revealed that the carboxyl tail of the G3 domain is subject to cleavage, however, it was protected from cleavage when it is linked to a GAG [79]. A recombinant aggrecan IG domain was used to demonstrate that aggrecanase can cleave this domain independent of the G1 and G2 domains and KS [72]. Cleavage of G1–G2 by aggrecanase was reduced once the KS chains were removed [62], whereas cleavage of recombinant full-length aggrecan by ADAMTS-4 was reduced once the CS chains were removed [80]. Cleavage of aggrecan by MMP-13 was found to occur first in the CS domain followed by the IG domain [60]. Recombinantly expressed G1–G2 was found to bind to both hyaluronan and link protein [73], with the majority of binding occurring in the B and B′ subdomains of aggrecan G1 [69]. The G3 domain, and particularly the C-type lectin subdomain, was found to bind to known lectin ligands including tenascin-R, -C and fibulin-2 [81]. The G1 domain of aggrecan has been shown to reduce chondrocyte attachment [65].

A perlecan/aggrecan chimera has been expressed in COS-7 cells to investigate the involvement of non-GAG-bearing domains in directing GAG attachment to GAG-bearing domains [64]. The chimeras produced were perlecan domain I with the G3 domain of aggrecan (I/G3) as well as the CS domain of aggrecan with perlecan domains II and III (CS/II/III). Both chimeras were produced as two populations, one decorated with GAGs and the other not, and the GAGs were determined to be attached to the CS region. The CS/II/III construct was almost entirely decorated with CS, whereas the I/G3 construct was decorated with both CS and HS.

Neurocan

Neurocan is a CS PG related to the aggrecan family and is expressed in neural tissue. Recombinant fragments expressed in HEK-293 cells were shown to interact with the neural cell-adhesion molecule, N-CAM [82], as well as tenascin-C [83] and HS PGs suggesting that it may be involved in guiding and modulating the growth of neurons [84].

Versican

Versican, also known as CSPG2, is a large CS PG that can form large aggregates through interactions with hyaluronan (HA) and can also bind to other ECM proteins, chemokines and cell-surface molecules. Versican is a multifunctional molecule with roles in cell adhesion, matrix assembly, cell migration and proliferation [85]. The chicken homologue of human versican is called PG-M. The versican gene is composed of 15 exons with exons 3–6 encoding the G1 domain, exons 7–8 encoding the G2 domain and exons 9–14 encoding the G3 domain. RNA splicing occurs in exons 7 and 8, which that encode for the GAG-attachment sites, resulting in the expression of four isoforms denoted V0, V1, V2 and V3 (Fig. 1). The V3 isoform does not contain either exon 7 or 8 and is hence not a PG.

image

Figure 1. Splice variants of versican [197]. UTR, untranslated region; SP, signal peptide; HABR, hyaluronan-binding region; GAGα, glycosaminoglycan α-binding region; GAGβ, glycosaminoglycan β-binding region; EGF, epidermal growth factor repeat; CR, complement regulatory protein repeat. The G1 domain is the HABR while the G3 domain contains exons 9–14.

Download figure to PowerPoint

Many different fragments of versican have been produced recombinantly, while few are decorated with GAGs (Table 2). Full-length versican has been expressed in CHO cells [86] and found to be decorated with CS. A fusion protein of the G1, 15% of the GAG-binding region and the G3 domain (also called mini-versican), derived from the chicken versican gene has been transiently expressed in COS-7 and stably expressed in NIH3T3 cells which was found to be a 150 kDa protein core decorated with 40–100 kDa CS [87-89]. Mini-versican was later expressed in chicken chondrocytes [90] and U87 astrocytoma cells [91]. Domains 1 and 3 together with the GAG domain and link protein have been expressed in COS-7 and NIH3T3 cells [89]. The link protein was used to increase secretion of the recombinant product. A fusion protein containing the GAG domain and domain 3 was found to exhibit a range of relative molecular masses by western blotting and assumed to be decorated with GAGs, however their presence was not confirmed [89].

Table 2. Recombinantly expressed forms of versican. nd, not determined; ns, not specified; no GAG, not decorated with GAGThumbnail image of

Many other recombinant forms of versican have been reported in the literature, however, they are not decorated with GAGs either because they do not containing exons 7 and 8 or are expressed in systems that do not decorate the protein core with GAGs, such as E. coli. The G1 domain, also known as the HA-binding region, has been expressed in NIH3T3 murine fibroblasts [86], Drosophila [92], High Five insect cells with a yield of 1–2 mg·L−1 [67] and bacteria [93]. The α- and β-GAG domains (exons 7 and 8) of versican have been expressed in E. coli, however, these constructs were not decorated with GAGs [94]. The G3 domain has been expressed in E. coli [88, 93, 95], whereas the lectin region (exons 11–13) of the G3 domain has been expressed in CHO [96] and HEK-293 cells [97].

Recombinant expression of versican has led to discoveries of its role in cancer through cell adhesion and migration studies. Recombinant full-length versican in the presence of HA has been shown to promote pericellular matrix formation in ovarian cancer cells, which promotes their motility and invasion in vitro, whereas treatment of these cells with recombinantly expressed versican induced cell invasion through an ECM barrier [98]. Mini-versican has been shown to enhance murine fibroblast proliferation which was attributed to the G3 domain [88], whereas the G1 domain has also been implicated through decreasing cell–substratum adhesion [89]. This form of versican has also been shown to inhibit mesenchymal chondrogenesis, which was also attributed to the G3 domain [87], and promote astrocytoma cell migration via the G1 domain [99]. Expression of this form of versican in chicken chondrocytes was found to promote proliferation through the G1 domain, destabilizing adhesion and the two EGF-like repeats stimulating proliferation [90]. Overexpression of G1 and G1/G3 domains in ovo resulted in enhanced cartilage deposition [100]. Domain I of human versican was found to induce spondylitis in the lumbar spine and sacroiliitis in BALB/c mice [67].

Recombinant expression of versican has also enabled an understanding of the role of the different domains. The presence of the G1 domain in constructs was found to inhibit expression, secretion and GAG decoration, whereas the presence of the G3 domain enhanced product secretion [87-90]. The G1 domain was found to form HA-dependent ternary complexes with link protein [101], whereas the HA-binding region was found to bind HA [86]. The C-type lectin domain was found to self-aggregate in dimer and multimer complexes [102], bind with high affinity to fibulin-1 [97, 103] and possesses carbohydrate-binding activity [96]. The C-terminal region of versican has been reported to bind heparin and HS in a Ca2+-dependent manner [95]. The P-selectin glycoprotein ligand-1 has been shown to bind to the versican G3 domain and mediates cell aggregation [91].

Bikunin

Bikunin, also known as urinary trypsin inhibitor, urinastatin and ulinastatin, is a CS PG. Bikunin is mostly found covalently linked via the CS chain to one or two of three heavy chain proteins designated HC1, HC2 and HC3 [104] named inter-α-trypsin inhibitor (bikunin, HC1 and HC2) and pre-α-inhibitor (bikunin and HC3) [105]. Bikunin is most widely known for its serine protease inhibitory activity [106], although it has also been investigated for its therapeutic activities in acute pancreatitis [107] and plays a role in the organization of hyaluronan in the ECM. Bikunin has a 20 kDa protein core and is predominantly synthesized by hepatocytes, where it is decorated with a CS chain as well as heavy chain proteins. It is transcribed from the α1-microglobulin/bikunin precursor gene in a precursor form with the α1-microglobulin protein N-terminal to the bikunin protein core, which is cleaved in the Golgi prior to decoration of the bikunin protein core at serine 10 with CS and subsequent attachment of the HC proteins [108]. Inter-α-trypsin inhibitor and pre-α-inhibitor are secreted by cells and have been termed PGs, however, bikunin is the only PG in these complexes because it is the only protein decorated with an O-linked CS chain on a serine residue [109]. The HC proteins are attached via an ester bond between the CS chain of bikunin and the a-carbon of the C-terminal amino acid of the heavy chains [110]. The cosynthesis of α1-microglobulin and bikunin is intriguing because they are not known to have a functional connection. Bikunin is most commonly isolated from urine as this form is not substituted with heavy chain proteins and it is naturally present in high abundance. Recombinant human bikunin has been successfully transiently expressed in COS-7 cells [111] and well as stably expressed in E. coli [112] and P. pastoris [113, 114], whereas rat α1-microglobulin/bikunin has been expressed in Sf9 insect cells [115] and COS-1 cells [116]. The PG form of bikunin has been recombinantly expressed in COS-7 cells decorated with ~ 30–50 kDa CS [111]. This form of bikunin was secreted by the cells as either the precursor form with α1-microglobulin, as bikunin alone or decorated with HC proteins. The PG form of bikunin has also been expressed in COS-1 cells in the precursor form with α1-microglobulin decorated with ~ 23-kDa CS and another form not decorated with CS [116]. Similar results were found in the insect expression system where bikunin was secreted as the precursor protein with α1-microglobulin or in its mature form in high concentrations [115], however, it was not decorated with CS. Bikunin expressed in P. pastoris was found to yield 55 mg·L−1 active protein with two protein cores of 24 and 21 kDa [114], whereas a fusion construct of bikunin with domain II of human serum albumin has been reported to produce a similar yield in P. pastoris [113].

Bikunin has also been shown to inhibit tumour invasion in vitro, which is dependent upon its anti-plasmin activity and urokinase-type plasminogen activator receptors [117]. A fusion protein of bikunin domain II and urokinase-type plasminogen activator was expressed in E. coli and found to be more effective at inhibiting cell-surface plasmin and in vitro cancer cell invasion than bikunin or urokinase-type plasminogen activator alone [117, 118]. Domain II was chosen because residues 78–136 have been reported to be responsible for the antimetastatic activity of bikunin [117], however, domain I contains the CS attachment site.

Perlecan

Perlecan, the major HS PG of basement membranes and other connective tissues, is a modular molecule with five structural domains. The molecular mass of the protein core is ~ 470 kDa whereas the molecular mass of the PG that includes the covalently attached GAG chains is in the range 600–700 kDa. The complete PG has been expressed in both HEK-293 and JAR choriocarcinoma cells and shown to interact in an HS-dependent fashion with activin A, a member of the TGF-β superfamily [119]. Of the five domains, the N-terminal domain I is the smallest with a molecular mass of ~ 20 kDa, and has been shown to contain a sperm protein, enterokinase and agrin module similar to that seen in mucins, and three well-characterized GAG-attachment sites, identified by the sequence Ser–Gly–Asp at residues Ser65, Ser71 and Ser76. Amino acid residues upstream of this region, as well as domains to the C-terminus, have been shown to be important in determining what type of GAG ultimately decorates each of the serine residues [120]. Domain I was first expressed in CHO cells [121], then in insect cells [122] and has subsequently been expressed in COS-7 [120] and HEK-293 cells [123-127]. In all of the mammalian systems, recombinant domain I was expressed as a PG mostly decorated with HS, whereas expression in conjunction with C-terminal domains of perlecan or as a fusion protein with enhanced green fluorescent protein resulted in only HS decoration [120, 124]. The HS attached to domain I was shown to be important for the binding of growth factors such as fibroblast growth factor (FGF)-2 [8, 125, 128], vascular endothelial growth factor-165 [126] and BMP-2 [129], as well as the basement membrane protein, laminin [130]. Domain II has homology to the low-density lipoprotein receptor and was expressed as a complete and correctly folded domain in HEK-293 cells [131]. The positions of the cysteine residues are strictly conserved suggesting that they are important for the tertiary structure of this domain. Domain III shares homology with structures present in the laminin α and γ chains as well as possessing EGF-like motifs and has been expressed in E. coli in its entirety [132] and as three separate, but overlapping, recombinant fragments in HEK-293 cells [133]. The highest affinity binding of platelet-derived growth factor BB isoform has been mapped to the laminin-type IV and laminin type EGF-like repeat 3 regions of this domain [134]. Despite the presence of an RGD motif in one of them, none of the recombinant fragments interacted with either α5β1 or αvβ3 integrins and no cell binding to any of the recombinant fragments could be demonstrated. This is in contrast to the same domain expressed in HT-1080 cells in which cells were shown to bind in an RGD-dependent fashion [135]. A recombinant fragment from this domain was shown to bind to WARP, which is an ECM molecule expressed by chondrocytes that is a member of the von Willebrand factor A domain superfamily [136]. Domain IV is the largest of the domains and consists of multiple IgG modules similar to those found in the neural cell-adhesion molecule. The number of the IgG motifs varies between species with the human perlecan sequence possessing 21 motifs, whereas the mouse perlecan sequence contains 14 [137]. This domain has also been expressed as overlapping fragments, which have been shown to bind to the basement membrane nidogens, fibronectin and fibulin-2 [138, 139]. Domain V is the most C-terminal of the domains present in the protein core, and is made up of three regions with homology to the globular domains of the laminin α chain, which is interspersed with four epidermal growth factor-like repeats. The mouse sequence for domain V was expressed in HEK-293 cells and was decorated with either HS or CS [140-142]. The human sequence representing domain V (Leu3611 to Ser4391) was expressed in HEK-293 cells and also shown to be decorated with either HS or CS [143], whereas the recombinant product known as endorepellin (Glu3687 to Ser4391) when transfected into the same HEK-293 cells was expressed without GAG chains [144] suggesting that the missing 76 amino acids may be important for correct glycosylation at this site or that the glycosylation of recombinant PGs is variable and dependent on the expression system. Interestingly, when the sequence from domain V of the Drosophila melanogaster homologue of perlecan, unc-52, was expressed in HEK-293 cells, it was also produced as a protein without GAG decoration [145]. The presence of GAG chains on these recombinant products may provide insights into the role of the perlecan molecule given that the interaction of recombinant domain V with nidogen, fibulin [140], laminin [146] or PRELP [147], an ECM protein that binds to collagen and is involved in matrix assembly, are all dependent on the presence of the GAG chains. By contrast, interactions with either α-dystroglycan [148] or the α2β1 integrin [149] have both been shown to be protein core dependent. Interestingly, removal of the GAG chains from recombinant domain V has been shown to enhance cell binding, suggesting that the presence of the carbohydrate inhibits the interaction with the integrin [143].

Endocan

The serum-borne PG, endocan, which is highly expressed in the vasculature around tumours, has been expressed in HEK-293 cells [150] and shown to have a relatively longer CS/DS chain than the endocan purified from endothelial cells. Given this, they had a similar disaccharide composition suggesting that their microstructures, which are responsible for binding growth factors and cytokines, are very similar [7].

Type XVIII collagen

The C-terminal fragment of this HS PG is known as endostatin and has been expressed in COS-7 cells. This region of type XVIII collagen, which does not contain GAG-attachment sites, has been expressed as a 20 kDa protein. Although its mechanism of action is independent of HS/heparin [151], endostatin expressed by HEK-293 cells was shown to bind to heparin [152]. Endostatin was first described in 1997 as an inhibitor of angiogenesis and it was hypothesized that it might be useful as an anti-cancer therapeutic [153], however, despite 15 years of intensive investigation in many cell and animal models, it has not been shown conclusively to have long-term clinical benefit. The mechanism of action of endostatin on cancer cells has been extensively studied but remains elusive. Although other groups have also successfully expressed fragments of type XVIII collagen and investigated its proteolysis by MMPs [154], nobody has successfully expressed full-length type XVIII collagen as an HS PG and this remains a challenge for the field moving forward.

Type XV collagen

Collagen type XV, like type XVIII collagen, contains an anti-angiogenic fragment called restin that has been expressed recombinantly [155], which cross-reacts with an antibody to endostatin. This recombinant fragment has been shown to inhibit the growth of tumours when injected into tumour-bearing animals [156]. Type XV collagen is a CS PG present in the basement membrane [157, 158] and ECM in close association with collagens where it may be involved in the fibrotic response [159]. It was expressed in insect cells and shown to regulate the adhesion and migration of both fibroblasts and fibrosarcoma cells and interacted with fibronectin, laminin and to a lesser extent vitronectin [160].

Cell-surface proteoglycans

  1. Top of page
  2. Abstract
  3. Introduction
  4. Extracellular matrix proteoglycans
  5. Cell-surface proteoglycans
  6. Intracellular proteoglycans
  7. Conclusions
  8. References

Cell-surface PGs provide a mechanism for cells to interact with a wide variety of ECM components including enabling the formation of receptor–ligand complexes. Cell-surface PGs can themselves be shed to form soluble PGs. Although HS is found on a variety of cell-surface proteins, it is found consistently on two major families of membrane-bound PGs – the syndecans and the glypicans. In addition, the cell-surface CS PGs, CD44 and CSPG4, are described.

Syndecans

The syndecans are a family of four cell-surface HS PGs that span the cell membrane and are important for cell motility and bind growth factors such as FGF-2 and ECM molecules. Different splice forms of syndecan-1 were transfected into Madine–Darby canine kidney cells, which were mostly produced as HS PGs, however, in some cases a mixed population of HS- and CS-decorated PGs were produced [161]. Syndecans-1 and -4 have been studied extensively using recombinant-based expression systems to investigate their role in binding to laminin [162], as well as the migration, proliferation and differentiation of cells. For example, mouse fibroblasts expressing recombinant syndecan-1 were shown to have activated intracellular adhesion pathways via the αvβ3 integrin [163]. The ectodomain containing the HS chains can be shed by proteinases and growth factor activation [164] and this has been shown to promote cell migration [165], which has ramifications for both wound healing and cancer progression. Full-length and truncated forms of syndecan-1 were transfected into mesenchymal-derived tumour cells and shown to modulate the epithelial to mesenchymal transition of the cells [166]. The ectodomain of syndecan-4 was expressed in E. coli, which promoted cell attachment but failed to assemble focal adhesions [167] suggesting that the HS chains might play a role. The ectodomain of syndecan-1 was expressed in CHO cells and shown to be decorated with HS that contained significant amounts of the disaccharides, 2-O-sulfated iduronic acid–N-sulfated, 6-sulfated glucosamine and 2-O-sulfated iduronic acid–N-sulfated glucosamine which bound FGF2, collagen type I, fibronectin and laminin [168]. A recombinant fusion of syndecan-4 and FGF-1 was engineered and isolated from transfected CHO cell medium. This fusion PG was decorated with both HS and CS chains and was active on endothelial cells in angiogenesis assays [169].

Glypicans

There are six members of the glypican family of cell-surface HS PGs and these, like the syndecan family, have been shown to interact with growth factors and ECM molecules via their HS chain. However, unlike the syndecans, the glypicans do not span the cell membrane, but instead are anchored in the membrane via a glycosylphosphotidyl inositol moiety. Human myelogenous leukemia (K562) cells transfected with glypican-1 and the FGF receptor-1 (iiic splice variant) had an increased signalling capacity in the presence of FGF-2, supporting the hypothesis that glypican-1 was involved in growth factor signalling [170]. Glypican-4 was expressed in neural precursor cells and shown to also interact with FGF-2 via its HS chains [171]. Interestingly, the ARH 77 B-lymphoid cell line adhered to collagen type I when the cells were transfected with either syndecan-2 or -4, but did not adhere to collagen type I when transfected with glypican-1 [172]. Furthermore, when glypican-1 was expressed in HEK-293 cells the cells did not bind to the LG4 domain of laminin α4 chain, suggesting that glypican-1 might have more defined binding interactions with growth factors such as FGF-2 and vascular endothelial growth factor-165 [173] rather than the ECM [171]. However, Slit-2, which is an extracellular protein involved in embryonic development, has been shown to interact specifically with the HS attached to recombinant glypican-1 [174]. Soluble recombinant glypican-1 lacking the glycosylphosphotidyl inositol anchor was shown to inhibit the growth of hepatocellular carcinoma cells in culture potentially by interfering with growth factor activation [175].

Glypican-1 ectodomain was expressed in HEK-293 cells and shown to be produced as a HS PG as well as a nondecorated protein core that was also N-glycanated and N-nitrosylated, which modulated the production of nitric oxide that could oxidize unsubstituted glucosamine residues present in the HS chains [176]. Other experiments using fusion constructs containing the various extracellular domains of glypican-1 showed that when the globular domain was present, the recombinant was decorated with HS and if this domain was absent, it was decorated with CS [177].

CD44

CD44 has some spliced forms that contain the exon V3 and have been shown to be decorated with HS that can bind FGF-2 and heparin binding-epidermal growth factor (HB-EGF) [178]. When the CD44 V3–10, V3 and V8–10 forms were expressed in conjunction with exons V4–7, they contained relatively lower sulfated HS, indicating that splicing events may have distal effects on the sulfation levels of the HS that in turn may affect the way CD44 interacts with growth factors [179].

Chondroitin sulfate proteoglycan 4 (CSPG4)

CSPG4, also known as high molecular mass melanoma-associated antigen (HMW-MAA), melanoma-associated CS PG or gp240, is a large integral membrane CS PG present on the cell surface of immature progenitor cells in several developing tissue types [180]. It is also expressed on some types of malignant cells including melanomas, glioblastomas and chondrosarcomas [181-184]. The presence of CSPG4 in these cell types suggests a role for this molecule in cell proliferation and/or differentiation. The rat homologue of CSPG4 is called nerve/glial antigen 2 (NG2) which has been shown to have a large extracellular region divided into three domains as well as a transmembrane domain and a short cytoplasmic domain. Each of the extracellular domains of human CSPG4 has been expressed in CHO cells as well as fusions of domains 1 and 2 and domains 1 and 3. Each of these constructs also contained the transmembrane and cytoplasmic domains. In addition, rat NG2 was expressed in the CHO cells, however, it was not characterized with respect to GAG decoration [44]. Most of the recombinant expression has been performed with rat NG2 cDNA. Rat neural cells (B28 cell line) and human glioma cells (U251MG cell line) have been transfected to express full-length NG2 [180]. Recombinant domains of NG2 have also been expressed including the entire extracellular domain (domains 1–3), domains 1 and 2, domain 2 and domain 3 in HEK-293 cells [185]. NG2 domain 2 was expressed at a yield of 0.3 μg·mL−1, whereas the entire extracellular domain was expressed at a concentration of 8 μg·mL−1 indicating that there might be differences in the stability of the different constructs. Recombinantly expressed NG2 was found to be expressed as two major populations, one without GAG decoration and the other decorated with between 50 and 300 kDa of CS with protein core of 300 kDa, suggesting that the protein core was decorated with CS in a similar manner to the endogenously expressed PG [13]. This same phenomenon has been reported for NG2 expressed in HEK-293 cells and COS-7 cells as either the full protein core of regions that included the extracellular domain 2 [185, 186]. In addition, the PG form of NG2 has been reported as the expected full protein core of 300 kDa as well as two shorter forms of 275 and 290 kDa. The smaller forms were found to be produced by proteolytic cleavage of the extracellular domain near the transmembrane domain from trypsin as well as increased protein kinase C activity that was thought to increase the abundance of proteases such as metalloproteinases [13].

The recombinantly expressed forms of NG2 have been used to explore some of the functions of the endogenously produced NG2 in terms of collagen binding, growth factor binding and cellular responses. Through the use of deletion mutants it was possible to determine that although there are 13 potential GAG-attachment sites on the NG2 protein core, it is only decorated with one CS chain at amino acid 999 [187]. Recombinantly expressed full-length NG2 has been reported to bind and anchor collagen type VI at the cell surface [180] and to modulate cell morphology [188]. Deletion mutants of full-length NG2 were able to demonstrate that the interaction between NG2 and collagen type VI involved the extracellular domain 2 [187] and that the interaction may involve the CS chain [185, 189]. Interestingly, the CS that decorates domain 2 of NG2 plays a role in mediating collagen types V and VI binding when NG2 is bound to a substrate and collagen is in solution, however, when collagen is bound and NG2 is in solution, the CS does not play a role in the binding [185]. This suggests that the conformation of NG2 is important for its interactions with collagen. The recombinantly expressed extracellular domains of NG2 were also able to support FGF-2 binding in a CS-dependent fashion [190]. The CS attached to recombinantly expressed NG2 domain 2 was found to inhibit neurite growth and induce growth cone collapse to a similar extent as either recombinantly expressed NG2 domains 1 or 3, however, when recombinantly expressed NG2 domain 2 was treated with chondroitinase ABC to remove the CS, it was no longer inhibitory [186].

Intracellular proteoglycans

  1. Top of page
  2. Abstract
  3. Introduction
  4. Extracellular matrix proteoglycans
  5. Cell-surface proteoglycans
  6. Intracellular proteoglycans
  7. Conclusions
  8. References

Serglycin is an heparin/HS/CS PG that is produced by many different cell types including endothelial cells [191], neutrophils and mast cells [192], and has been shown to be important for binding and packaging proteases into intracytoplasmic secretory granules. It is also present in the α-granules of platelets where it binds and packages platelet factor 4 and the serglycin in mast cells is thought to be the major source of commercial heparin manufactured from porcine intestinal mucosa or bovine lungs. It has been expressed in pancreatic cancer cells (AR4-2J) where the presence of GAG was shown to be important for the correct trafficking of the serglycin to the granules [193]. The sulfation content of the GAG on serglycin has also been shown to be important for the apical-basolateral sorting when it was transfected into Madine–Darby canine kidney with the higher sulfated forms being trafficked to the basolateral region for secretion [194]. Interestingly, the presence of GAG chains on serglycin has also been shown to be highly expressed by nasopharyngeal carcimonas and may be involved in promoting metastasis [195].

Conclusions

  1. Top of page
  2. Abstract
  3. Introduction
  4. Extracellular matrix proteoglycans
  5. Cell-surface proteoglycans
  6. Intracellular proteoglycans
  7. Conclusions
  8. References

There are still many challenges awaiting the bioengineer/molecular biologist who designs and expresses PGs in cells. Many of the extracellular PGs are large and contain many domains, whereas many of the cell-surface PGs contain stretches of hydrophobic residues and the mucin-like nature of some intracellular PGs means that repetitive serine–glycine sequences need to be expressed and glycosylated. The other significant challenge of expressing PGs is the importance of the structure of their GAG chains including length, sulfation level and content of iduronic acid and how this maps to their biological functions. We are just beginning to understand how the glycosylation of PGs enhances and modulates the functions attributable to the protein core and many of these effects can only be studied using recombinant forms of the PGs. The attributes described above provide significant and on-going challenges but it is important that future research efforts are focused on these challenges so that the recombinant forms that are produced mimic the natural PG structures, which will enable them to be used as research reagents that will help us address many hypotheses in the laboratory today, and which will guide the development of new classes of therapeutics useful for many clinical applications into the future.

References

  1. Top of page
  2. Abstract
  3. Introduction
  4. Extracellular matrix proteoglycans
  5. Cell-surface proteoglycans
  6. Intracellular proteoglycans
  7. Conclusions
  8. References
  • 1
    Terra VS, Mills DC, Yates LE, Abouelhadid S, Cuccui J & Wren BW (2012) Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design. J Med Microbiol 61, 919926.
  • 2
    Huang CJ, Lin H & Yang X (2012) Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J Ind Microbiol Biotechnol 39, 383399.
  • 3
    Mattanovich D, Branduardi P, Dato L, Gasser B, Sauer M & Porro D (2012) Recombinant protein production in yeasts. Methods Mol Biol 824, 329358.
  • 4
    Pavsic M, Vito T & Lenarcic B (2008) Purification and characterization of a recombinant human testican-2 expressed in baculovirus-infected Sf9 insect cells. Protein Expr Purif 58, 132139.
  • 5
    McQuillan DJ, Seo NS, Hocking AM & McQuillan CI (2001) Recombinant expression of proteoglycans in mammalian cells. Utility and advantages of the vaccinia virus/T7 bacteriophage hybrid expression system. Methods Mol Biol 171, 201219.
  • 6
    Zhu J (2012) Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 30, 11581170.
  • 7
    Sarrazin S, Lyon M, Deakin JA, Guerrini M, Lassalle P, Delehedde M & Lortat-Jacob H (2010) Characterization and binding activity of the chondroitin/dermatan sulfate chain from Endocan, a soluble endothelial proteoglycan. Glycobiology 20, 13801388.
  • 8
    Whitelock J, Ma J, Davies N, Nielsen N, Chuang C, Rees M, Iozzo RV, Knox S & Lord M (2008) Recombinant heparan sulfate for use in tissue engineering applications. J Chem Technol Biotechnol 83, 496504.
  • 9
    Knox S, Fosang AJ, Last K, Melrose J & Whitelock J (2005) Perlecan from human epithelial cells is a hybrid heparan/chondroitin/keratan sulfate proteoglycan. FEBS Lett 579, 50195023.
  • 10
    Multhaupt HA & Couchman JR (2012) Heparan sulfate biosynthesis: methods for investigation of the heparanosome. J Histochem Cytochem 60, 908915.
  • 11
    Whitelock JM & Iozzo RV (2005) Heparan sulfate: a complex polymer charged with biological activity. Chem Rev 105, 27452764.
  • 12
    Baik JY, Gasimli L, Yang B, Datta P, Zhang F, Glass CA, Esko JD, Linhardt RJ & Sharfstein ST (2012) Metabolic engineering of Chinese hamster ovary cells: towards a bioengineered heparin. Metab Eng 14, 8190.
  • 13
    Nishiyama A, Lin XH & Stallcup WB (1995) Generation of truncated forms of the NG2 proteoglycan by cell surface proteolysis. Mol Biol Cell 6, 18191832.
  • 14
    Linhardt RJ & Liu J (2012) Synthetic heparin. Curr Opin Pharmacol 12, 217219.
  • 15
    Hocking AM, Shunomura T & McQuillan DJ (1998) Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol 17, 119.
  • 16
    Pearson CH, Winterbottom N, Fackre DS, Scott PG & Carpenter MR (1983) The NH2-terminal amino acid sequence of bovine skin proteodermatan sulfate. J Biol Chem 258, 1510115104.
  • 17
    Yamaguchi Y & Ruoslahti E (1988) Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature 336, 244246.
  • 18
    Tenni R, Viola M, Welser F, Sini P, Giudici C, Rossi A & Tira ME (2002) Interaction of decorin with CNBr peptides from collagens I and II. Evidence for multiple binding sites and essential lysyl residues in collagen. Eur J Biochem 269, 14281437.
  • 19
    Bidanset DJ, Guidry C, Rosenberg LC, Choi HU, Timpl R & Hook M (1992) Binding of the proteoglycan decorin to collagen type VI. J Biol Chem 267, 52505256.
  • 20
    Ramamurthy P, Hocking AM & McQuillan DJ (1996) Recombinant decorin glycoforms. J Biol Chem 271, 1957819584.
  • 21
    von Marschall Z & Fisher LW (2010) Decorin is processed by three isoforms of bone morphogenetic protein-1 (BMP1). Biochem Biophys Res Commun 391, 13741378.
  • 22
    Al Haj Zen A, Lafont A, Durand E, Brasselet C, Lemarchand P, Godeau G & Gogly B (2003) Effect of adenovirus-mediated overexpression of decorin on metalloproteinases, tissue inhibitors of metalloproteinases and cytokines secretion by human gingival fibroblasts. Matrix Biol 22, 251258.
  • 23
    Shimizukawa M, Ebina M, Narumi K, Kikuchi T, Munakata H & Nukiwa T (2003) Intratracheal gene transfer of decorin reduces subpleural fibroproliferation induced by bleomycin. Am J Physiol Lung Cell Mol Physiol 284, L526L532.
  • 24
    Kitagawa H, Oyama M, Masayama K, Yamaguchi Y & Sugahara K (1997) Structural variations in the glycosaminoglycan–protein linkage region of recombinant decorin expressed in Chinese hamster ovary cells. Glycobiology 7, 11751180.
  • 25
    Engel S, Isenmann S, Ständer M, Rieger J, Bähr M & Weller M (1999) Inhibition of experimental rat glioma growth by decorin gene transfer is associated with decreased microglial infiltration. J Neuroimmunol 99, 1318.
  • 26
    Svensson L, Närlid I & Oldberg A (2000) Fibromodulin and lumican bind to the same region on collagen type I fibrils. FEBS Lett 470, 178182.
  • 27
    Reed CC, Gauldie J & Iozzo RV (2002) Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 21, 36883695.
  • 28
    Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG & Lowenstein PR (2004) Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther 11, 721732.
  • 29
    Huijun W, Long C, Zhigang Z, Feng J & Muyi G (2005) Ex vivo transfer of the decorin gene into rat glomerulus via a mesangial cell vector suppressed extracellular matrix accumulation in experimental glomerulonephritis. Exp Mol Pathol 78, 1724.
  • 30
    Hu Y, Sun H, Owens RT, Wu J, Chen YQ, Berquin IM, Perry D, O'Flaherty JT & Edwards IJ (2009) Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11, 10421053.
  • 31
    Sugars EV, Waddington RJ & Embery G (2002) The interaction of recombinant decorin with α2HS-glyocprotein – implications for structural and functional investigations. Protein Expr Purif 25, 180188.
  • 32
    Landrygan-Bakri J, Wilson MJ, Williams DW, Lewis MA & Waddington RJ (2012) Real-time monitoring of the adherence of Streptococcus anginosus group bacteria to extracellular matrix decorin and biglycan proteoglycans in biofilm formation. Res Microbiol 163, 436447.
  • 33
    Hering TM, Kollar J, Huynh TD & Varelas JB (1996) Purification and characterization of decorin core protein expressed in Escherichia coli as a maltose-binding protein fusion. Anal Biochem 240, 98108.
  • 34
    Gu J, Nakayama Y, Nagai K & Wada Y (1997) The production and purification of functional decorin in a baculovirus system. Biochem Biophys Res Commun 232, 9195.
  • 35
    Seo NS, Hocking AM, Höök M & McQuillan DJ (2005) Decorin core protein secretion is regulated by N-linked oligosaccharide and glycosaminoglycan additions. J Biol Chem 280, 4277442784.
  • 36
    Geng Y, McQuillan DJ & Roughley PJ (2006) SLRP interaction can protect collagen fibrils from cleavage by collagenases. Matrix Biol 25, 484491.
  • 37
    Kalamajski S, Aspberg A & Oldberg A (2007) The decorin sequence SYIRIADTNIT binds collagen type I. J Biol Chem 282, 1606216067.
  • 38
    Dugan TA, Yang VW, McQuillan DJ & Höök M (2003) Decorin binds fibrinogen in a Zn2+-dependent interaction. J Biol Chem 278, 1365513662.
  • 39
    Groeneveld TWL, Oroszlán M, Owens RT, Faber-Krob MC, Bakker AC, Arlaud GJ, McQuillan DJ, Kishore U, Daha MR & Roos A (2005) Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collectins. J Immunol 175, 47154723.
  • 40
    Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B & Iozzo RV (1997) Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 100, 149157.
  • 41
    Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RT, McQuillan DJ & Iozzo RV (2008) An antimetastatic role for decorin in breast cancer. Am J Pathol 173, 844855.
  • 42
    Grant DS, Yenisey C, Rose RW, Tootell M, Santra M & Iozzo RV (2002) Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 21, 47654777.
  • 43
    Shintani K, Matsumine A, Kusuzaki K, Morikawa J, Matsubara T, Wakabayashi T, Araki K, Satonaka H, Wakabayashi H, Iino T et al. (2008) Decorin suppresses lung metastases of murine osteosarcoma. Oncol Rep 19, 15331539.
  • 44
    Border WA, Noble NA, Yamamoto T, Tomooka S & Kagami S (1992) Antagonists of transforming growth factor-β: a novel approach to treatment of glomerulonephritis and prevention of glomerulosclerosis. Kidney Int 41, 566570.
  • 45
    Masuda H, Takakura Y & Hashida M (1999) Pharmacokinetics and disposition characteristics of recombinant decorin after intravenous injection into mice. Biochim Biophys Acta 1426, 420428.
  • 46
    Logan A, Baird A & Berry M (1999) Decorin attenuates gliotic scar formation in the rat cerebral hemisphere. Exp Neurol 159, 504510.
  • 47
    Fukushima K, Badlani N, Usas A, Riano F, Fu F & Huard J (2001) The use of an antifibrosis agent to improve muscle recovery after laceration. Am J Sports Med 29, 394402.
  • 48
    Järveläinen H, Vernon RB, Gooden MD, Francki A, Lara S, Johnson PY, Kinsella MG, Sage EH & Wight TN (2004) Overexpression of decorin by rat arterial smooth muscle cells enhances contraction of type I collagen in vitro. Arterioscler Thromb Vasc Biol 24, 6772.
  • 49
    Yan W, Wang P, Zhao CX, Tang J, Xiao X & Wang DW (2009) Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/Smad and p38 mitogen-activated protein kinase signaling pathways. Hum Gene Ther 20, 11901200.
  • 50
    Hocking AM, Strugnell RA, Ramamurthy P & McQuillan DJ (1996) Eukaryotic expression of recombinant biglycan. J Biol Chem 271, 1957119577.
  • 51
    Schönherr E, Beavan LA, Hausser H, Kresse H & Culp LA (1993) Differences in decorin expression by papillary and reticular fibroblasts in vivo and in vitro. Biochem J 290, 893899.
  • 52
    Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67, 609652.
  • 53
    Kresse H, Seidler DG, Muller M, Breuer E, Hausser H, Roughley PJ & Schonherr E (2001) Different usage of the glycosaminoglycan attachment sites of biglycan. J Biol Chem 276, 1341113416.
  • 54
    Mercado ML, Amenta AR, Hagiwara H, Rafii MS, Lechner BE, Owens RT, McQuillan DJ, Froehner SC & Fallon JR (2006) Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J 20, 17241726.
  • 55
    Svensson L, Heinegärd D & Oldberg A (1995) Decorin-binding sites for collagen type I are mainly located in leucine-rich repeats 4–5. J Biol Chem 270, 2071220716.
  • 56
    Wiberg C, Heinegärd DW, Timpl R & Morgelin M (2002) Biglycan organizes collagen VI into hexagonal-like networks resembling tissue structures. J Biol Chem 277, 4912049126.
  • 57
    Schönherr E, Witsch-Prehm P, Harrach B, Robenek H, Rauterberg J & Kresse H (1995) Interaction of biglycan with type I collagen. J Biol Chem 270, 27762783.
  • 58
    Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, Khurana TS & Fallon JR (2011) Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci USA 108, 762767.
  • 59
    Rafii MS, Hagiwara H, Mercado ML, Seo NS, Xu T, Dugan T, Ownes RT, Hook M, McQuillan DJ, Young MF et al. (2006) Biglycan binds to α- and γ-sarcogylcan and regulates their expression during development. J Cell Physiol 209, 439447.
  • 60
    Miwa HE, Gerken TA, Huynh TD, Flory DM & Hering TM (2006) Mammalian expression of full-length bovine aggrecan and link protein: formation of recombinant proteoglycan aggregates and analysis of proteolytic cleavage by ADAMTS-4 and MMP-13. Biochim Biophys Acta 1760, 472486.
  • 61
    Kiani C, Lee V, Cao L, Chen L, Wu Y, Zhang Y, Adams ME & Yang BB (2001) Role of aggrecan domains in biosynthesis, modification by glycosaminoglycans and product secretion. Biochem J 354, 199207.
  • 62
    Poon CJ, Plaas AH, Keene DR, McQuillan DJ, Last K & Fosang AJ (2005) N-linked keratan sulfate in the aggrecan interglobular domain potentiates aggrecanase activity. J Biomed 280, 2361523621.
  • 63
    Yang BB, Yang BL & Goetinick PF (1996) Construction and expression of a functional recombinant gene for proteoglycan. Ann NY Acad Sci 785, 356359.
  • 64
    Doege K, Chen X, Cornuet PK & Hassell J (1997) Non-glycosaminoglycan bearing domains of perlecan and aggrecan influence the utilization of sites for heparan and chondroitin sulfate synthesis. Matrix Biol 16, 211221.
  • 65
    Cao L, Zhang Y & Yang BB (1998) Expression of the G1 domain of aggrecan interferes with chondrocyte attachment and adhesion. Matrix Biol 17, 379392.
  • 66
    Li LN, Zhang DQ, Zhou KY, Cartman A, Leroux JY, Poole AR & Zhang YP (2000) Isolation and characteristics of autoreactive T cells specific to aggrecan G1 domain from rheumatoid arthritis patients. Cell Res 10, 3949.
  • 67
    Shi S, Ciurli C, Cartman A, Pidoux I, Poole AR & Zhang Y (2003) Experimental immunity to the G1 domain of the proteoglycan versican induces spondylitis and sacroiliitis, of a kind seen in human spondylarthropathies. Arthritis Rheum 48, 29032915.
  • 68
    Oliver BL, Cronin CG, Bue C, Hand AR & Tanzer ML (2003) Two alanines juxtaposed to aggrecan's G1 domain alter its intracellular localisation. J Cell Biochem 90, 592607.
  • 69
    Watanabe H, Cheung SC, Itano N, Kimata K & Yamada Y (1997) Identification of hyaluronan-binding domains of aggrecan. J Biol Chem 272, 2805728065.
  • 70
    Chen TLL, Wang PY, Luo W, Gwon SS, Flay NW, Zheng J, Guo C, Tanzer ML & Vertel BM (2001) Aggrecan domains expected to traffic through the exocytic pathway are misdirected to the nucleus. Exp Cell Res 263, 224235.
  • 71
    Fushimi K, Troeberg L, Nakamura H, Lim NH & Nagase H (2008) Functional differences of the catalytic and non-catalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem 283, 67066716.
  • 72
    Hughes CE, Buttner FH, Eidenmuller B, Caterson B & Bartnik E (1997) Utilization of a recombinant substrate rAgg1 to study the biochemical properties of aggrecananse in cell culture systems. J Biol Chem 272, 2026920274.
  • 73
    Mercuri FA, Doege KJ, Arner EC, Pratta MA, Last K & Fosang AJ (1999) Recombinant human aggrecan G1–G2 exhibits native binding properties and substrate specificity for matrix metalloproteinases and aggrecanase. J Biol Chem 274, 3238732395.
  • 74
    Halberg DF, Proulx G, Doege K, Yamada Y & Drickamer K (1988) A segment of the cartilage proteoglycan core protein has lectin-like activity. J Biol Chem 263, 94869490.
  • 75
    Dudhia J, Davidson CM, Wells TM, Vynios DH, Hardingham TE & Bayliss MT (1996) Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage. Biochem J 313, 933940.
  • 76
    Kiani C, Chen L, Lee V, Zheng PS, Wu Y, Wen J, Cao L, Adams ME, Sheng W & Yang BB (2003) Identification of the motifs and amino acids in aggrecan G1 and G2 domains involved in product secretion. Biochemistry 42, 72267237.
  • 77
    Luo W, Kuwada TS, Chandrasekaran L, Zheng J & Tanzer ML (1996) Divergent secretory behaviour of the opposite ends of aggrecan. J Biol Chem 271, 1644716450.
  • 78
    Chen L, Wu Y, Lee V, Kiani C, Adams ME, Yao Y & Yang BB (2002) The folded modules of aggrecan G3 domain exert two separable functions in glycosaminoglycan modification and product secretion. J Biol Chem 277, 26572665.
  • 79
    Lee V, Chen L, Paiwand F, Cao L, Wu Y, Inman R, Adams ME & Yang BB (2002) Cleavage of the carboxyl tail from the G3 domain of aggrecan but not versican and identification of the amino acids involved in the degradation. J Biol Chem 277, 2227922288.
  • 80
    Miwa HE, Gerken TA & Hering TM (2006) Effects of covalently attached chondroitin sulfate on aggrecan cleavage by ADAMTS-4 and MMP-13. Matrix Biol 25, 534545.
  • 81
    Day JM, Olin AI, Murdoch AD, Canfield A, Sasaki T, Timpl R, Hardingham TE & Aspberg A (2004) Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins. J Biol Chem 279, 1251112518.
  • 82
    Retzler C, Gohring W & Rauch U (1996) Analysis of neurocan structures interacting with the neural cell adhesion molecule N-CAM. J Biol Chem 271, 2730427310.
  • 83
    Milev P, Fischer D, Haring M, Schulthess T, Margolis RK, Chiquet-Ehrismann R & Margolis RU (1997) The fibrinogen-like globe of tenascin-C mediates its interactions with neurocan and phosphacan/protein-tyrosine phosphatase-zeta/beta. J Biol Chem 272, 1550115509.
  • 84
    Akita K, Toda M, Hosoki Y, Inoue M, Fushiki S, Oohira A, Okayama M, Yamashina I & Nakada H (2004) Heparan sulphate proteoglycans interact with neurocan and promote neurite outgrowth from cerebellar granule cells. Biochem J 383, 129138.
  • 85
    Wight TN (2002) Versican: a versatile extracellular matrix proteoglycan. Curr Opin Cell Biol 14, 617623.
  • 86
    LeBaron RG, Zimmermann DR & Ruoslahti E (1992) Hyaluronate binding properties of versican. J Biol Chem 267, 1000310010.
  • 87
    Zhang Y, Cao L, Kiani CG, Yang BL & Yang BB (1998) The G3 domain of versican inhibits mesenchymal chondrogenesis via the epidermal growth factor-like motifs. J Biol Chem 273, 3305433063.
  • 88
    Zhang Y, Cao L, Yang BL & Yang BB (1998) The G3 domain of versican enhanced cell proliferation via epidermal growth factor-like motifs. J Biol Chem 273, 2134221351.
  • 89
    Yang BL, Zhang Y, Cao L & Yang BB (1999) Cell adhesion and proliferation mediated through the G1 domain of versican. J Cell Biochem 72, 210220.
  • 90
    Zhang Y, Cao L, Kiani CG, Yang BL, Hu W & Yang BB (1999) Promotion of chondrocyte proliferation by versican mediated by G1 domain and EGF-like repeats. J Cell Biochem 73, 445457.
  • 91
    Zheng PS, Vais D, laPierre D, Liang YY, Lee V, Yang BL & Yang BB (2004) PG-M/versican binds to P-selectin glycoprotein ligand-1 and mediates leukocyte aggregation. J Cell Sci 117, 58875895.
  • 92
    McVey GF, Dudhia J & Day AJ (2001) Recombinant expression of link protein, aggrecan and versican. Int J Exp Pathol 82, A1A25.
  • 93
    Zimmermann DR, Dours-Zimmermann MT, Schubert M & Bruckner-Tuderman L (1994) Versican is expressed in the proliferating zone in the epidermis and in association with the elastic network of the dermis. J Cell Biol 124, 817825.
  • 94
    Milev P, Maurel P, Chiba A, Mievissen M, Popp S, Yamaguchi Y, Margolis RK & Margolis RU (1998) Differential regulation of expression of hyaluronan-binding proteoglycans in developing brain: aggrecan, versican, neurocan and brevican. Biochem Biophys Res Commun 247, 207212.
  • 95
    Ujita M, Shinomura T, Ito K, Kitagawa Y & Kimata K (1994) Expression and binding activity of the carboxyl-terminal portion of the core protein of PG-M, a large chondroitin sulfate proteoglycan. J Biol Chem 269, 2760327609.
  • 96
    Aspberg A, Binkert C & Ruoslahti E (1995) The versican C-type lectin domain recognizes the adhesion protein tenascin-R. Proc Natl Acad Sci USA 92, 1059010594.
  • 97
    Aspberg A, Adam S, Kostka G, Timpl R & Heinegärd D (1999) Fibulin-1 is a ligand for the C-type lectin domains of aggrecan and versican. J Biol Chem 274, 2044420449.
  • 98
    Ween MP, Hummitzsch K, Rodgers RJ, Oehler MK & Ricciardelli C (2011) Veriscan induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clin Exp Metastasis 28, 113125.
  • 99
    Ang YC, Zhang Y, Cao L, Yang BL, Young B, Kiani CG, Lee V, Allan K & Yang BB (1999) Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J Neuropathol Exp Neurol 58, 597605.
  • 100
    Hudson KA, Abndrews K, Early J, Mjaatvedt CH & Capehart AA (2010) Versican G1 domain and V3 isoform overexpression results in increased chondrogenesis in the developing chick limb in ovo. Anat Rec (Hoboken) 293, 16691678.
  • 101
    Seyfried NT, McVey GF, Almond A, Mahoney DJ, Dudhia J & Day AJ (2005) Expression and purification of functionally active hyaluronan-binding domains from human cartilage link protein, aggrecan and versican: formation of ternary complexes with defined hyaluronan oligosaccharides. J Biol Chem 280, 54355448.
  • 102
    Ney A, Booms P, Epple G, Mörgelin M, Guo G, Kettelgerdes G, Gessner R & Robinson PN (2006) Calcium-dependent self-association of the C-type lectin domain of versican. Int J Biochem Cell Biol 38, 2329.
  • 103
    Olin AI, Mörgelin M, Sasaki T, Timpl R, Heinegård D & Aspberg A (2001) The proteoglycans aggrecan and versican form networks with fibulin-2 through their lectin domain binding. J Biol Chem 276, 12531261.
  • 104
    Enghild JJ, Thøgersen IB, Pizzo SV & Salvesen G (1989) Analysis of inter-α-trypsin inhibitor and a novel trypsin inhibitor, pre-α-trypsin inhibitor, from human plasma. Polypeptide chain stoichiometry and assembly by glycan. J Biol Chem 264, 1597515981.
  • 105
    Enghild JJ, Salvesen G, Thogersen IB, Valnickova Z, Pizzo SV & Hefta SA (1993) Presence of the protein-glycosaminoglycan-protein covalent cross-link in the inter-α-inhibitor-related proteinase inhibitor heavy chain 2/bikunin. J Biol Chem 268, 87118716.
  • 106
    Fries E & Blom AM (2000) Bikunin – not just a plasma proteinase inhibitor. Int J Biochem Cell Biol 32, 125137.
  • 107
    Michalski C, Piva F, Balduyck M, Mizon C, Burnouf T, Huart JJ & Mizon J (1994) Preparation and properties of a therapeutic inter-alpha-trypsin inhibitor concentrate from human plasma. Vox Sang 67, 329336.
  • 108
    Bratt T, Olsson H, Sjöberg M, Jergil B & Akerström B (1993) Cleavage of the α1-microglobulin–bikunin precursor in the Golgi apparatus of rat liver cells. Biochim Biophys Acta 1157, 147154.
  • 109
    Chi L, Wolff JJ, Laremore TN, Restaino OF, Xie J, Schiraldi C, Toida T, Amster IJ & Linhardt RJ (2008) Structural analysis of bikunin glycosaminoglycan. J Am Chem Soc 130, 26172625.
  • 110
    Enghild JJ, Salvesen G, Hefta SA, Thøgersen IB, Rutherfurd S & Pizzo SV (1991) Chondroitin 4-sulfate covalently cross-links the chains of the human blood protein pre-alpha-inhibitor. J Biol Chem 266, 747751.
  • 111
    Martin-Vandelet N, Paris S, Bourguignon J, Sesboüé R, Martin JP & Diarra-Mehrpour M (1999) Assembly and secretion of recombinant chains of human inter-α-trypsin inhibitor in COS-7 cells. Eur J Biochem 259, 476484.
  • 112
    Brinkmann T, Schäfers J, Gürtler L, Kido H, Niwa Y, Katunuma N & Tschesche H (1997) Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV1 replication in H9 cells by recombinant aprotinin and bikunin homologues. J Protein Chem 16, 651660.
  • 113
    Gou XH, Liu YY, Chen QL, Tang JJ, Liu DY, Zou L, Wu XY & Wang W (2012) High level expression of bikunin in Pichia pastoris by fusion of human serum albumin. AMB Express 2, 17.
  • 114
    Wang J, Yan F, Wang D, Ban L, Sun N, Li C, Zhang T & Yan W (2008) Expression and purification of active recombinant human bikunin in Pichia pastoris. Protein Expr Purif 60, 127131.
  • 115
    Bratt T & Akerstrom B (1995) Expression of rat alpha(1)-microglobulin-bikunin in baculovirus-transformed insect cells. Protein Expr Purif 6, 431438.
  • 116
    Blom AM, Thuveson M & Fries E (1997) Intracellular coupling of bikunin and the heavy chain of rat pre-α-inhibitor in COS-1 cells. Biochem J 328, 185191.
  • 117
    Kobayashi H, Shinohara H, Ohi H, Sugimura M, Terao T & Fujie M (1994) Urinary trypsin inhibitor (UTI) and fragments derived from UTI by limited proteolysis efficiently inhibit tumor cell invasion. Clin Exp Metastasis 12, 117128.
  • 118
    Kobayashi H, Gotoh J, Hirashima Y, Fujie M, Sugino D & Terao T (1995) Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem 270, 83618366.
  • 119
    Li S, Shimono C, Norioka N, Nakano I, Okubo T, Yagi Y, Hayashi M, Sato Y, Fujisaki H, Hattori S et al. (2010) Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity. J Biol Chem 285, 3664536655.
  • 120
    Dolan M, Horchar T, Rigatti B & Hassell JR (1997) Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis. J Biol Chem 272, 43164322.
  • 121
    Kokenyesi R & Silbert JE (1995) Formation of heparan sulfate or chondroitin/dermatan sulfate on recombinant domain I of mouse perlecan expressed in Chinese hamster ovary cells. Biochem Biophys Res Commun 211, 262267.
  • 122
    Groffen AJ, Buskens CA, Tryggvason K, Veerkamp JH, Monnens LA & van den Heuvel LP (1996) Expression and characterization of human perlecan domains I and II synthesized by baculovirus-infected insect cells. Eur J Biochem 241, 827834.
  • 123
    Costell M, Mann K, Yamada Y & Timpl R (1997) Characterization of recombinant perlecan domain I and its substitution by glycosaminoglycans and oligosaccharides. Eur J Biochem 243, 115121.
  • 124
    Graham LD, Whitelock JM & Underwood PA (1999) Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains. Biochem Biophys Res Commun 256, 542548.
  • 125
    Yang WD, Gomes RR Jr, Alicknavitch M, Farach-Carson MC & Carson DD (2005) Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds. Tissue Eng 11, 7689.
  • 126
    Muthusamy A, Cooper CR & Gomes RR Jr (2010) Soluble perlecan domain I enhances vascular endothelial growth factor-165 activity and receptor phosphorylation in human bone marrow endothelial cells. BMC Biochem 11, 43.
  • 127
    Ellis AL, Pan W, Yang G, Jones K, Chuang C, Whitelock JM & DeCarlo AA (2010) Similarity of recombinant human perlecan domain 1 by alternative expression systems bioactive heterogenous recombinant human perlecan D1. BMC Biotechnol 10, 66.
  • 128
    Casper CL, Yang W, Farach-Carson MC & Rabolt JF (2007) Coating electrospun collagen and gelatin fibers with perlecan domain I for increased growth factor binding. Biomacromolecules 8, 11161123.
  • 129
    DeCarlo AA, Belousova M, Ellis AL, Petersen D, Grenett H, Hardigan P, O'Grady R, Lord M & Whitelock JM (2012) Perlecan domain 1 recombinant proteoglycan augments BMP-2 activity and osteogenesis. BMC Biotechnol 12, 60.
  • 130
    Sasaki T, Costell M, Mann K & Timpl R (1998) Inhibition of glycosaminoglycan modification of perlecan domain I by site-directed mutagenesis changes protease sensitivity and laminin-1 binding activity. FEBS Lett 435, 169172.
  • 131
    Costell M, Sasaki T, Mann K, Yamada Y & Timpl R (1996) Structural characterization of recombinant domain II of the basement membrane proteoglycan perlecan. FEBS Lett 396, 127131.
  • 132
    Murdoch AD, Liu B, Schwarting R, Tuan RS & Iozzo RV (1994) Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem 42, 239249.
  • 133
    Schulze B, Mann K, Battistutta R, Wiedemann H & Timpl R (1995) Structural properties of recombinant domain III of perlecan containing a globular domain inserted into an epidermal-growth-factor-like motif. Eur J Biochem 231, 551556.
  • 134
    Gohring W, Sasaki T, Heldin CH & Timpl R (1998) Mapping of the binding of platelet-derived growth factor to distinct domains of the basement membrane proteins BM-40 and perlecan and distinction from the BM-40 collagen-binding epitope. Eur J Biochem 255, 6066.
  • 135
    Chakravarti S, Horchar T, Jefferson B, Laurie GW & Hassell JR (1995) Recombinant domain III of perlecan promotes cell attachment through its RGDS sequence. J Biol Chem 270, 404409.
  • 136
    Allen JM, Bateman JF, Hansen U, Wilson R, Bruckner P, Owens RT, Sasaki T, Timpl R & Fitzgerald J (2006) WARP is a novel multimeric component of the chondrocyte pericellular matrix that interacts with perlecan. J Biol Chem 281, 73417349.
  • 137
    Hopf M, Gohring W, Mann K & Timpl R (2001) Mapping of binding sites for nidogens, fibulin-2, fibronectin and heparin to different IG modules of perlecan. J Mol Biol 311, 529541.
  • 138
    Hopf M, Gohring W, Kohfeldt E, Yamada Y & Timpl R (1999) Recombinant domain IV of perlecan binds to nidogens, laminin–nidogen complex, fibronectin, fibulin-2 and heparin. Eur J Biochem 259, 917925.
  • 139
    Kohfeldt E, Sasaki T, Gohring W & Timpl R (1998) Nidogen-2: a new basement membrane protein with diverse binding properties. J Mol Biol 282, 99109.
  • 140
    Brown JC, Sasaki T, Gohring W, Yamada Y & Timpl R (1997) The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur J Biochem 250, 3946.
  • 141
    Friedrich MV, Gohring W, Morgelin M, Brancaccio A, David G & Timpl R (1999) Structural basis of glycosaminoglycan modification and of heterotypic interactions of perlecan domain V. J Mol Biol 294, 259270.
  • 142
    Tapanadechopone P, Hassell JR, Rigatti B & Couchman JR (1999) Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan. Biochem Biophys Res Commun 265, 680690.
  • 143
    Jung M, Lord MS, Cheng B, Lyons JG, Alkhouri H, Hughes M, McCarthy S, Iozzo RV & Whitelock JM (2013) Mast cells produce novel shorter forms of perlecan that contain functional endorepellin: a role in angiogenesis and wound healing. J Biol Chem 288, 32893304.
  • 144
    Mongiat M, Sweeney SM, San Antonio JD, Fu J & Iozzo RV (2003) Endorepellin, a novel inhibitor of angiogenesis derived from the C-terminus of perlecan. J Biol Chem 278, 42384249.
  • 145
    Friedrich MV, Schneider M, Timpl R & Baumgartner S (2000) Perlecan domain V of Drosophila melanogaster. Sequence, recombinant analysis and tissue expression. Eur J Biochem 267, 31493159.
  • 146
    Ettner N, Gohring W, Sasaki T, Mann K & Timpl R (1998) The N-terminal globular domain of the laminin alpha1 chain binds to alpha1beta1 and alpha2beta1 integrins and to the heparan sulfate-containing domains of perlecan. FEBS Lett 430, 217221.
  • 147
    Bengtsson E, Morgelin M, Sasaki T, Timpl R, Heinegard D & Aspberg A (2002) The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchor. J Biol Chem 277, 1506115068.
  • 148
    Talts JF, Andac Z, Gohring W, Brancaccio A & Timpl R (1999) Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins. EMBO J 18, 863870.
  • 149
    Bix G, Fu J, Gonzalez EM, Macro L, Barker A, Campbell S, Zutter MM, Santoro SA, Kim JK, Hook M et al. (2004) Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 166, 97109.
  • 150
    Adam E, Sarrazin S, Landolfi C, Motte V, Lortat-Jacob H, Lassalle P & Delehedde M (2008) Efficient long-term and high-yielded production of a recombinant proteoglycan in eukaryotic HEK293 cells using a membrane-based bioreactor. Biochem Biophys Res Commun 369, 297302.
  • 151
    Chang Z, Choon A & Friedl A (1999) Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. Am J Pathol 155, 7176.
  • 152
    Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L, Lindahl U, Hohenester E & Timpl R (1999) Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin. EMBO J 18, 62406248.
  • 153
    O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR & Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277285.
  • 154
    Heljasvaara R, Nyberg P, Luostarinen J, Parikka M, Heikkila P, Rehn M, Sorsa T, Salo T & Pihlajaniemi T (2005) Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res 307, 292304.
  • 155
    Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E & Timpl R (2000) Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol 301, 11791190.
  • 156
    Ramchandran R, Dhanabal M, Volk R, Waterman MJ, Segal M, Lu H, Knebelmann B & Sukhatme VP (1999) Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 255, 735739.
  • 157
    Li D, Clark CC & Myers JC (2000) Basement membrane zone type XV collagen is a disulfide-bonded chondroitin sulfate proteoglycan in human tissues and cultured cells. J Biol Chem 275, 2233922347.
  • 158
    Amenta PS, Scivoletti NA, Newman MD, Sciancalepore JP, Li D & Myers JC (2005) Proteoglycan-collagen XV in human tissues is seen linking banded collagen fibers subjacent to the basement membrane. J Histochem Cytochem 53, 165176.
  • 159
    Hagg PM, Hagg PO, Peltonen S, Autio-Harmainen H & Pihlajaniemi T (1997) Location of type XV collagen in human tissues and its accumulation in the interstitial matrix of the fibrotic kidney. Am J Pathol 150, 20752086.
  • 160
    Hurskainen M, Ruggiero F, Hagg P, Pihlajaniemi T & Huhtala P (2010) Recombinant human collagen XV regulates cell adhesion and migration. J Biol Chem 285, 52585265.
  • 161
    Romaris M, Coomans C, Ceulemans H, Bruystens AM, Vekemans S & David G (1999) Molecular polymorphism of the syndecans. Identification of a hypo-glycanated murine syndecan-1 splice variant. J Biol Chem 274, 1866718674.
  • 162
    Carulli S, Beck K, Dayan G, Boulesteix S, Lortat-Jacob H & Rousselle P (2012) Cell surface proteoglycans syndecan-1 and -4 bind overlapping but distinct sites in laminin alpha3 LG45 protein domain. J Biol Chem 287, 1220412216.
  • 163
    McQuade KJ, Beauvais DM, Burbach BJ & Rapraeger AC (2006) Syndecan-1 regulates alphavbeta5 integrin activity in B82L fibroblasts. J Cell Sci 119, 24452456.
  • 164
    Fitzgerald ML, Wang Z, Park PW, Murphy G & Bernfield M (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148, 811824.
  • 165
    Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M & Sato H (2003) Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 278, 4076440770.
  • 166
    Zong F, Fthenou E, Mundt F, Szatmari T, Kovalszky I, Szilak L, Brodin D, Tzanakakis G, Hjerpe A & Dobra K (2011) Specific syndecan-1 domains regulate mesenchymal tumor cell adhesion, motility and migration. PLoS ONE 6, e14816.
  • 167
    Whiteford JR & Couchman JR (2006) A conserved NXIP motif is required for cell adhesion properties of the syndecan-4 ectodomain. J Biol Chem 281, 3215632163.
  • 168
    Viklund L, Loo BM, Hermonen J, El-Darwish K, Jalkanen M & Salmivirta M (2002) Expression and characterization of minican, a recombinant syndecan-1 with extensively truncated core protein. Biochem Biophys Res Commun 290, 146152.
  • 169
    Yoneda A, Asada M, Oda Y, Suzuki M & Imamura T (2000) Engineering of an FGF–proteoglycan fusion protein with heparin-independent, mitogenic activity. Nat Biotechnol 18, 641644.
  • 170
    Steinfeld R, Van Den Berghe H & David G (1996) Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican. J Cell Biol 133, 405416.
  • 171
    Hagihara K, Watanabe K, Chun J & Yamaguchi Y (2000) Glypican-4 is an FGF2-binding heparan sulfate proteoglycan expressed in neural precursor cells. Dev Dyn 219, 353367.
  • 172
    Liu W, Litwack ED, Stanley MJ, Langford JK, Lander AD & Sanderson RD (1998) Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions. J Biol Chem 273, 2282522832.
  • 173
    Gengrinovitch S, Berman B, David G, Witte L, Neufeld G & Ron D (1999) Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem 274, 1081610822.
  • 174
    Zhang F, Ronca F, Linhardt RJ & Margolis RU (2004) Structural determinants of heparan sulfate interactions with Slit proteins. Biochem Biophys Res Commun 317, 352357.
  • 175
    Zittermann SI, Capurro MI, Shi W & Filmus J (2010) Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 126, 12911301.
  • 176
    Svensson G & Mani K (2009) S-Nitrosylation of secreted recombinant human glypican-1. Glycoconj J 26, 12471257.
  • 177
    Chen RL & Lander AD (2001) Mechanisms underlying preferential assembly of heparan sulfate on glypican-1. J Biol Chem 276, 75077517.
  • 178
    Bennett KL, Jackson DG, Simon JC, Tanczos E, Peach R, Modrell B, Stamenkovic I, Plowman G & Aruffo A (1995) CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 128, 687698.
  • 179
    Piepkorn M, Hovingh P, Bennett KL & Linker A (1999) Heparan sulfate composition of alternatively spliced CD44 fusion proteins. Biochem Biophys Res Commun 257, 839842.
  • 180
    Nishiyama A & Stallcup WB (1993) Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface. Mol Biol Cell 4, 10971108.
  • 181
    Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ & Reisfeld RA (1996) Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 93, 97109715.
  • 182
    Schrappe M, Klier FG, Spiro RC, Waltx TAR, Reisfeld RA & Gladson CL (1991) Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res 51, 49864993.
  • 183
    Leger O, Johnson-Leger C, Jackson E, Coles B & Dean C (1994) The chondroitin sulfate proteoglycan NG2 is a tumour-specific antigen on the chemically induced rat chondrosarcoma HSN. Int J Cancer 58, 700705.
  • 184
    Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, Ferrone CR, Favino E, Koya Y, Campoli MR et al. (2010) CSPG4 in cancer: multiple roles. Curr Mol Med 10, 419429.
  • 185
    Tillet E, Ruggiero F, Nishiyama A & Stallcup WB (1997) The membrane-spanning proteoglycan NG2 binds to collagens V and VI through the central nonglobular domain of its core protein. J Biol Chem 272, 1076910776.
  • 186
    Ughrin YM, Chen ZJ & Levine JM (2003) Multiple regions of the NG2 proteoglycan inhibit neurite growth and induce growth cone collapse. J Neurosci 23, 175186.
  • 187
    Burg MA, Nishiyama A & Stallcup WB (1997) A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. Exp Cell Res 235, 254264.
  • 188
    Tillet E, Gential B, Garrone R & Stallcup WB (2002) NG2 proteoglycan mediates β1 integrin-independent cell adhesion and spreading on collagen VI. J Cell Biochem 86, 726736.
  • 189
    Burg MA, Tillet E, Timpl R & Stallcup WB (1996) Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. J Biol Chem 271, 2611026116.
  • 190
    Goretzki L, Burg MA, Grako KA & Stallcup WB (1999) High-affinity binding of basic fibroblast growth factor and platelet-derived growth factor-AA to the core protein of the NG2 proteoglycan. J Biol Chem 274, 1683116837.
  • 191
    Schick BP, Gradowski JF & San Antonio JD (2001) Synthesis, secretion, and subcellular localization of serglycin proteoglycan in human endothelial cells. Blood 97, 449458.
  • 192
    Braga T, Grujic M, Lukinius A, Hellman L, Abrink M & Pejler G (2007) Serglycin proteoglycan is required for secretory granule integrity in mucosal mast cells. Biochem J 403, 4957.
  • 193
    Biederbick A, Licht A & Kleene R (2003) Serglycin proteoglycan is sorted into zymogen granules of rat pancreatic acinar cells. Eur J Cell Biol 82, 1929.
  • 194
    Hafte TT, Fagereng GL, Prydz K, Grondahl F & Tveit H (2011) Protein core-dependent glycosaminoglycan modification and glycosaminoglycan-dependent polarized sorting in epithelial Madin–Darby canine kidney cells. Glycobiology 21, 457466.
  • 195
    Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, Ooi A, Peng LX, Lu WH, Zhang Z, Petillo D et al. (2011) Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res 71, 31623172.
  • 196
    Hasegawa K, Yoneda M, Kuwabara H, Miyaishi O, Itano N, Ohno A, Zako M & Isogai Z (2007) Versican, a major hyaluronan-binding component in the dermis, loses its hyaluronan-binding ability in solar elastosis. J Invest Dermatol 127, 16571663.
  • 197
    Naso MF, Zinmmermann DR & Iozzo RV (1994) Characterisation of the complete genomic structure of the human versican gene and functional analysis of its promoter. J Biol Chem 269, 3299933008.